Raymond James Financial
CLYM

Raymond James Financial’s Climb Bio CLYM Stock Holding History

Raymond James Financial’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Buy
25,239
+7,512
+42% +$77.6K ﹤0.01% 4770
2026
Q1 		$121K Buy
+17,727
New +$102K ﹤0.01% 4997
2025
Q3 		– Sell
-200
Closed -$248 – 6939
2025
Q2 		$248 Buy
+200
New +$249 ﹤0.01% 6757

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Raymond James Financial's CLYM Position: Q2 2026 in Review

Raymond James Financial increased its Climb Bio (CLYM) stake by 42% in Q2 2026, buying an estimated $77.6K and bringing the position to 25,239 shares worth $329K. The position accounts for ﹤0.01% of the portfolio, ranked #4770.

Raymond James Financial first reported a position in CLYM in Q2 2025 and has held it in 3 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Raymond James Financial held 25,239 shares of Climb Bio worth $329K as of Q2 2026.
  • Raymond James Financial bought 7,512 Climb Bio shares in Q2 2026, an estimated $77.6K.
  • Climb Bio made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4770 holding.
  • Raymond James Financial first reported a position in Climb Bio in Q2 2025 and has held it in 3 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.